AC Immune SA (ACIU) Form 6-K — Jun 11, 2026
AC Immune SA announced it will receive a $4 million research grant from The Vijay and Marie Goradia Charitable Foundation to support the development of its anti-alpha-synuclein active immunotherapy, ACI-7104, in early Parkinson’s disease. The grant will fund the extension of Part 1 of the ongoing Phase 2 VacSYn trial, allowing the company to assess long-term safety and efficacy of ACI-7104 for an additional two years.
Key figures
- Grant Amount
- 4000000
- Trial Name
- VacSYn
- Trial Phase
- Phase 2
- Grant Source
- The Vijay and Marie Goradia Charitable Foundation
- Data Readout Timing
- H2 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.